Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

French study tracks daily life changes in MS patients on newer drug

NCT ID NCT06157086

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 302 adults with multiple sclerosis in France who are starting the drug ofatumumab as part of their normal care. Researchers will measure how patients' quality of life changes after 12 months using a special questionnaire. The goal is to understand real-world benefits and satisfaction, not to test the drug itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

302 people

The number who actually took part.

Started

Dec 2023

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will be adult patients with MS (women and men) who have initiated treatment with ofatumumab (Kesimpta ®).

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female, 18 years of age or older 2. Patient with confirmed MS diagnosis 3. Patient initiating treatment with ofatumumab for the first time 4. Patient for which the decision to initiate treatment with ofatumumab was made by the doctor (investigator) in accordance with his/her usual practices independently of the study 5. Patient not opposed to participation in this study 6. Patient willing and able to complete patient questionnaires Exclusion Criteria: 1\. Patient treated with ofatumumab in the context of a clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis (MS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis (MS)

Contacts and locations

Locations

  • Novartis Investigative Site

    Angers, France, 49933, France

  • Novartis Investigative Site

    Paris, France, F-75571, France

  • Novartis Investigative Site

    Agen, 47923, France

  • Novartis Investigative Site

    Altkirch, 68130, France

  • Novartis Investigative Site

    Amiens, 80054, France

  • Novartis Investigative Site

    Belfort, 90000, France

  • Novartis Investigative Site

    Bordeaux, 33076, France

  • Novartis Investigative Site

    Boulogne-sur-Mer, 62200, France

  • Novartis Investigative Site

    Brest, 29200, France

  • Novartis Investigative Site

    Brunstatt Didenheim, 68350, France

  • Novartis Investigative Site

    Cahors, 46000, France

  • Novartis Investigative Site

    Chambéry, 73000, France

  • Novartis Investigative Site

    Cherbourg Octeville, 50102, France

  • Novartis Investigative Site

    Compiègne, 60200, France

  • Novartis Investigative Site

    Contamine-sur-Arve, 74130, France

  • Novartis Investigative Site

    Dax, 40107, France

  • Novartis Investigative Site

    Gonesse, 95503, France

  • Novartis Investigative Site

    Le Bouscat, 33110, France

  • Novartis Investigative Site

    Le Coudray, 28630, France

  • Novartis Investigative Site

    Lens, 62307, France

  • Novartis Investigative Site

    Libourne, 33505, France

  • Novartis Investigative Site

    Lille, 59000, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Lyon, 69008, France

  • Novartis Investigative Site

    Lyon, 69275, France

  • Novartis Investigative Site

    Mantes-la-Jolie, 78200, France

  • Novartis Investigative Site

    Marseille 01, 13001, France

  • Novartis Investigative Site

    Meaux, 77104, France

  • Novartis Investigative Site

    Metz-Tessy, 74374, France

  • Novartis Investigative Site

    Mont-de-Marsan, 40024, France

  • Novartis Investigative Site

    Montluçon, 03100, France

  • Novartis Investigative Site

    Montpellier, 34090, France

  • Novartis Investigative Site

    Mulhouse, 68100, France

  • Novartis Investigative Site

    Nîmes, 30029, France

  • Novartis Investigative Site

    Orsay, 91400, France

  • Novartis Investigative Site

    Paris, 75014, France

  • Novartis Investigative Site

    Paris, 75017, France

  • Novartis Investigative Site

    Poissy, 78303, France

  • Novartis Investigative Site

    Quint-Fonsegrives, 31130, France

  • Novartis Investigative Site

    Reims, 51092, France

  • Novartis Investigative Site

    Rennes, 35033, France

  • Novartis Investigative Site

    Saverne, 67700, France

  • Novartis Investigative Site

    Sélestat, 67600, France

  • Novartis Investigative Site

    Strasbourg, 67000, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Tours, 37044, France

  • Novartis Investigative Site

    Valence, 26953, France

  • Novartis Investigative Site

    Vannes, 56017, France

  • Novartis Investigative Site

    Villeurbanne, 69100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.